Pancreatic tumor
Conditions
Interventions
1. Dilute ICG 1 ampoule (25 mg) to 2.5 mg/mL with 10 mL of water for injection in the Japanese Pharmacopoeia.
2. Immediately after the start of surgery, the basic dose of diluted ICG is 0.1 mL (equiva
Sponsors
Ishikawa Yoshiya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with malignant or borderline malignant pancreatic tumor based on image findings, etc. 2. Patients undergoing robotic or laparoscopic pancreaticoduodenectomy or distal pancreatectomy. 3. Patients aged 18 years or older at the time of informed consent. 4. Patients who have given their written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of allergy to indocyanine green or iodinated contrast agents. 2. Patients with a history of gastric surgery or right-sided colon surgery (excluding appendectomy). 3. Patients who are pregnant, may be pregnant, or are lactating. 4. Patients who are judged as ineligible for registration by attending doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification rate of lymphatic flow | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Time required from ICG local injection to confirmation of lymphatic flow. 2. Number of ICG fluorescence positive lymph nodes. 3. Histopathological presence or absence of metastasis in ICG fluorescence-positive lymph nodes. 4. Frequency and incidence of adverse events . | — |
Contacts
Public ContactYoshiya Ishikawa
Institute of Science Tokyo Hospital
Outcome results
None listed